The CMS announced Tuesday that it will be allowing Medicare Advantage plans to negotiate lower prices for doctor-administered drugs covered under Part B as part of the Trump administration's broader effort to cut prescription drug costs. Effective next year, MA plans will be permitted to use a cost-saving tool called step therapy, which gives payers the option to offer patients the most-preferred and often least expensive therapy first, before moving them to a more expensive drug if the initial treatment is not effective.
CMS to let MA plans negotiate lower prices for Part B drugs
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.